MCID: BLR008
MIFTS: 53

Bilirubin Metabolic Disorder

Categories: Blood diseases, Metabolic diseases

Aliases & Classifications for Bilirubin Metabolic Disorder

MalaCards integrated aliases for Bilirubin Metabolic Disorder:

Name: Bilirubin Metabolic Disorder 12 15
Hyperbilirubinemia 12 77 38 30 56 6 45 15 74
Hyperbilirubinemia, Hereditary 45 74
Hereditary Hyperbilirubinemia 12
Hyperbilirubinaemia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2741
KEGG 38 H00208
NCIt 51 C84761
SNOMED-CT 69 14783006 20505009
ICD10 34 E80.6

Summaries for Bilirubin Metabolic Disorder

Disease Ontology : 12 An inherited metabolic disorder that involves elevated levels of bilirubin resulting from disruption of bilirubin metabolism.

MalaCards based summary : Bilirubin Metabolic Disorder, also known as hyperbilirubinemia, is related to hyperbilirubinemia, rotor type and crigler-najjar syndrome, type i, and has symptoms including muscle weakness, polydipsia and icterus. An important gene associated with Bilirubin Metabolic Disorder is UGT1A1 (UDP Glucuronosyltransferase Family 1 Member A1), and among its related pathways/superpathways are Porphyrin and chlorophyll metabolism and ABC transporters. The drugs carbamide peroxide and Liver Extracts have been mentioned in the context of this disorder. Affiliated tissues include liver, breast and testes.

Wikipedia : 77 Bilirubin is a yellow compound that occurs in the normal catabolic pathway that breaks down heme in... more...

Related Diseases for Bilirubin Metabolic Disorder

Diseases related to Bilirubin Metabolic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 273)
# Related Disease Score Top Affiliating Genes
1 hyperbilirubinemia, rotor type 34.5 ABCC2 ALB SLCO1B1
2 crigler-najjar syndrome, type i 31.9 SLC35A2 UGT1A UGT1A1 UGT1A6
3 obstructive jaundice 31.7 ALB F2 GGT1 GPT SLC17A5
4 gilbert syndrome 31.5 G6PD SLCO1B1 UGT1A1 UGT1A6 UGT1A7 UGT1A8
5 crigler-najjar syndrome, type ii 31.3 UGT1A UGT1A1 UGT1A6 UGT1A7 UGT1A8
6 kernicterus 30.8 ALB G6PD UGT1A1 UGT1A6
7 glucosephosphate dehydrogenase deficiency 30.6 G6PD HP SLCO1B1 UGT1A1
8 hepatitis a 30.4 ALB F2 GPT
9 neonatal jaundice 30.3 G6PD HMOX1 NR1I3 SLCO1B1 UGT1A1
10 cholestasis 30.1 ABCC2 F2 GGT1 GPT NR1I3 SLCO1B1
11 cholelithiasis 30.1 ALB GPT UGT1A1 UGT1A6
12 nonalcoholic steatohepatitis 30.0 F2 GPT SLC17A5
13 cholecystitis 30.0 ALB F2 GPT HP
14 hepatic coma 30.0 ALB F2 GPT
15 sickle cell anemia 30.0 F2 G6PD UGT1A1 UGT1A6
16 infantile liver failure syndrome 1 30.0 ALB F2 GPT SLC17A5
17 hemorrhagic fever 29.9 ALB F2 GPT
18 hepatitis e 29.9 ALB F2 GPT
19 alpha-thalassemia 29.9 G6PD HP UGT1A1
20 hepatitis 29.8 F2 GGT1 GPT SLC17A5
21 cholangitis 29.7 ALB F2 GGT1 GPT HP
22 cholangitis, primary sclerosing 29.6 ALB GGT1 GPT
23 analbuminemia 29.6 ALB F2 GPT SLC17A5
24 acute liver failure 29.6 ALB F2 GPT SLC17A5
25 alcoholic hepatitis 29.5 ADAMTS13 ALB F2 GPT SLC17A5
26 viral hepatitis 29.4 ALB F2 GGT1 GPT SLC17A5
27 liver cirrhosis 29.3 ALB F2 GGT1 GPT SLC17A5
28 liver disease 29.3 ALB F2 GGT1 GPT SLC17A5
29 hepatitis b 29.1 ALB F2 GGT1 GPT SLC17A5
30 hyperbilirubinemia, transient familial neonatal 12.6
31 hyperbilirubinemia, shunt, primary 12.3
32 hyperbilirubinemia, conjugated, type iii 12.0
33 chronic bilirubin encephalopathy 11.5
34 dubin-johnson syndrome 11.4
35 liver failure, infantile, transient 11.2
36 congenital intrauterine infection-like syndrome 11.2
37 bamforth syndrome 11.1
38 cryohydrocytosis 11.0
39 biliary atresia, extrahepatic 11.0
40 bile acid synthesis defect, congenital, 1 11.0
41 stomatin-deficient cryohydrocytosis with neurologic defects 11.0
42 obesity, early-onset, with adrenal insufficiency and red hair 11.0
43 congenital toxoplasmosis 11.0
44 antipyrine metabolism 10.4 ALB F2
45 non-a-e hepatitis 10.4 ALB F2
46 hepatoportal sclerosis 10.4 F2 GPT
47 epstein-barr virus hepatitis 10.4 ALB F2
48 fournier gangrene 10.3 ALB F2
49 heme oxygenase 1 deficiency 10.3 HMOX1 HP
50 abdominal tuberculosis 10.3 ALB F2

Graphical network of the top 20 diseases related to Bilirubin Metabolic Disorder:



Diseases related to Bilirubin Metabolic Disorder

Symptoms & Phenotypes for Bilirubin Metabolic Disorder

UMLS symptoms related to Bilirubin Metabolic Disorder:


muscle weakness, polydipsia, icterus, jaundice (not of newborn)

Drugs & Therapeutics for Bilirubin Metabolic Disorder

Drugs for Bilirubin Metabolic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 17)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
carbamide peroxide Approved Phase 1, Phase 2 124-43-6
2 Liver Extracts Phase 1, Phase 2
3
Acetylcholine Approved, Investigational Not Applicable 51-84-3 187
4
Orlistat Approved, Investigational Not Applicable 96829-58-2 3034010
5
Iron Approved, Experimental 7439-89-6, 15438-31-0 23925 27284
6 Botulinum Toxins, Type A Not Applicable
7 Neurotransmitter Agents Not Applicable
8 Acetylcholine Release Inhibitors Not Applicable
9 Cholinergic Agents Not Applicable
10 Peripheral Nervous System Agents Not Applicable
11 abobotulinumtoxinA Not Applicable
12 Botulinum Toxins Not Applicable
13 Neuromuscular Agents Not Applicable
14 Anti-Obesity Agents Not Applicable
15 Lipid Regulating Agents Not Applicable
16
Bilirubin Not Applicable 635-65-4, 69853-43-6 5280352 21252250
17 Hematinics

Interventional clinical trials:

(show all 12)
# Name Status NCT ID Phase Drugs
1 Safety Study of HepaStem for the Treatment of Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN) Completed NCT01765283 Phase 1, Phase 2
2 Gene Therapy for Severe Crigler Najjar Syndrome Recruiting NCT03466463 Phase 1, Phase 2
3 Gene Transfer Clinical Study in Crigler-Najjar Syndrome Recruiting NCT03223194 Phase 1, Phase 2
4 New Phototherapy Device to Treat Patients With Crigler-Najjar Disease Unknown status NCT02356978 Not Applicable
5 Long-term Safety Follow-up Study of Patients Having Received HepaStem (SAF001) Unknown status NCT02051049
6 Comparison of Biofeedback vs. Botox Injection to Treat Levator Ani Syndrome Unknown status NCT00564707 Not Applicable
7 Orlistat Treatment of Crigler-Najjar Disease Completed NCT00461799 Not Applicable orlistat
8 Clinical Assessment Study in Crigler-Najjar Syndrome Completed NCT03078881
9 Immunity Against AAV in Crigler Najjar Patient Completed NCT02302690
10 China Registry for Genetic / Metabolic Liver Diseases Recruiting NCT03131427 Standard of care
11 Biomarker for Gilbert Disease: BioGilbert Recruiting NCT02712138
12 HepaStem Long-Term Safety Registry Not yet recruiting NCT03343756

Search NIH Clinical Center for Bilirubin Metabolic Disorder

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: hyperbilirubinemia

Genetic Tests for Bilirubin Metabolic Disorder

Genetic tests related to Bilirubin Metabolic Disorder:

# Genetic test Affiliating Genes
1 Hyperbilirubinemia 30

Anatomical Context for Bilirubin Metabolic Disorder

MalaCards organs/tissues related to Bilirubin Metabolic Disorder:

42
Liver, Breast, Testes, Brain, Heart, Skin, Bone

Publications for Bilirubin Metabolic Disorder

Articles related to Bilirubin Metabolic Disorder:

(show top 50) (show all 1598)
# Title Authors Year
1
Hyperbilirubinemia predicts the infectious complications after esophagectomy for esophageal cancer. ( 30899455 )
2019
2
Hyperbilirubinemia Induces Pro-Apoptotic Effects and Aggravates Renal Ischemia Reperfusion Injury. ( 30673658 )
2019
3
Newborn Metabolic Profile Associated with Hyperbilirubinemia With and Without Kernicterus. ( 30369069 )
2019
4
Rates of Extreme Neonatal Hyperbilirubinemia and Kernicterus in Children and Adherence to National Guidelines for Screening, Diagnosis, and Treatment in Sweden. ( 30901042 )
2019
5
Phototherapy for neonatal hyperbilirubinemia and childhood eczema, rhinitis and wheeze. ( 29678409 )
2019
6
Effects of Gly71Arg mutation in UGT1A1 gene on neonatal hyperbilirubinemia: a systematic review and meta-analysis. ( 29179591 )
2019
7
Neonatal hyperbilirubinemia secondary to combined anti e and anti C isoimmunisation: a literature review. ( 29295661 )
2019
8
Prediction of Neonatal Hyperbilirubinemia Using 1st Day Serum Bilirubin Levels. ( 29450817 )
2019
9
Developmental influence of unconjugated hyperbilirubinemia and neurobehavioral disorders. ( 30397278 )
2019
10
Phototherapy is associated with the decrease in serum globulin levels in neonatal hyperbilirubinemia. ( 30588305 )
2019
11
Phototherapy for Neonatal Unconjugated Hyperbilirubinemia: Examining Outcomes by Level of Care. ( 30606776 )
2019
12
A Novel Whole Spectrum-based Non-invasive Screening Device for Neonatal Hyperbilirubinemia. ( 30640639 )
2019
13
Association between genetic polymorphism of heme oxygenase 1 promoter and neonatal hyperbilirubinemia: a meta-analysis. ( 30700176 )
2019
14
Neonatal hyperbilirubinemia: An evidence-based approach. ( 30724909 )
2019
15
Amphotericin B-Induced Hyperbilirubinemia. ( 30730333 )
2019
16
Prevalence and burden of illness of treated hemolytic neonatal hyperbilirubinemia in a privately insured population in the United States. ( 30744649 )
2019
17
The effect of intestinal flora on the neural development of severe hyperbilirubinemia neonates. ( 30779098 )
2019
18
Changes in total serum bilirubin during phototherapy in late preterm and term infants with non-haemolytic hyperbilirubinemia. ( 30831388 )
2019
19
Hyperbilirubinemia as a Predictor of Appendiceal Perforation: A Systematic Review and Diagnostic Test Meta-Analysis. ( 30834039 )
2019
20
Green LED phototherapy for neonatal hyperbilirubinemia: A randomized controlled trial. ( 30838731 )
2019
21
Knowledge of Neonatal Hyperbilirubinemia Among Primary Health Care Physicians: A Single-Center Experience. ( 30853790 )
2019
22
Association of a Delayed Cord-Clamping Protocol With Hyperbilirubinemia in Term Neonates. ( 30870273 )
2019
23
Efficacy and Safety of Steroid Therapy for Posttransplant Hyperbilirubinemia Caused by Early Allograft Dysfunction: A Randomized Controlled Trial. ( 30870403 )
2019
24
Easy Diagnosis of Jaundice: A Smartphone-based Nanosensor Bioplatform using Photoluminescent Bacterial Nanopaper for Point-of-Care Diagnosis of Hyperbilirubinemia. ( 30896150 )
2019
25
Probiotics for the management of neonatal hyperbilirubinemia: a systematic review of randomized controlled trials. ( 28823200 )
2019
26
Role of massage therapy on reduction of neonatal hyperbilirubinemia in term and preterm neonates: a review of clinical trials. ( 28870134 )
2019
27
Acute liver failure with extreme hyperbilirubinemia secondary to endocarditis-related severe mitral and tricuspid regurgitation: a challenge and an opportunity for surgeons. ( 29607182 )
2018
28
A Prospective Study on the Diagnostic Value of Hyperbilirubinemia as a Predictive Factor for Appendicular Perforation in Acute Appendicitis. ( 30405990 )
2018
29
Hyperbilirubinemia, Phototherapy, and Childhood Asthma. ( 30209075 )
2018
30
Clinical Value of Inflammation-Based Prognostic Scores to Predict the Resectability of Hyperbilirubinemia Patients with Potentially Resectable Hilar Cholangiocarcinoma. ( 30076591 )
2018
31
Vitamin B12 deficiency associated with hyperbilirubinemia and cholestasis in infants. ( 30034445 )
2018
32
Adding neonatal hyperbilirubinemia/bilirubin encephalopathy to the American Society for Apheresis Guidelines on Therapeutic Apheresis. ( 29193228 )
2018
33
Adding neonatal hyperbilirubinemia/bilirubin encephalopathy to the American Society for Apheresis Guidelines on Therapeutic Apheresis. ( 29193232 )
2018
34
Direct hyperbilirubinemia in newborns with gastroschisis. ( 30415437 )
2018
35
Direct hyperbilirubinemia in infants with congenital heart disease. ( 29178522 )
2018
36
An unexpectedly prolonged severe hyperbilirubinemia in a patient with pre-existing hepatitis A: a role of genetic predisposition? ( 30422796 )
2018
37
Gadoxetic acid-enhanced magnetic resonance imaging to predict paritaprevir-induced hyperbilirubinemia during treatment of hepatitis C. ( 29709031 )
2018
38
Tokyo-1 Mutation: Hereditary Spherocytosis in a Hispanic Newborn Presenting as Early Onset Severe Hyperbilirubinemia. ( 30207817 )
2018
39
Posaconazole-associated severe hyperbilirubinemia in acute myeloid leukemia following chemotherapy: A case report. ( 30613684 )
2018
40
Letter: tacrolimus may be hazardous in decompensated autoimmune liver disease with hyperbilirubinemia-authors' reply. ( 29878432 )
2018
41
Acute Isolated Hyperbilirubinemia as a Presentation of Alcoholic Liver Disease: A Case Report and Literature Review. ( 29623226 )
2018
42
Paraneoplastic hyperbilirubinemia in metastatic prostate cancer and review of the current literature. ( 30668309 )
2018
43
Risk Factors for Sensorineural Hearing Loss in Neonatal Hyperbilirubinemia. ( 30083525 )
2018
44
Brief Report: Hyperbilirubinemia Is Associated With a Decreased Risk of Carotid Atherosclerosis in HIV-Infected Patients on Virological Suppression. ( 30204718 )
2018
45
Effect of Hyperbilirubinemia on Hepatic Hypertrophy after Portal Vein Embolization and Liver Failure after Heatectomy in Primary Biliary Malignancy. ( 30527653 )
2018
46
Severe Direct Hyperbilirubinemia as a Consequence of Right Heart Failure in Congenital Heart Disease. ( 27154793 )
2018
47
Severe neonatal hyperbilirubinemia induces temporal and occipital lobe seizures. ( 29750802 )
2018
48
Intraoperative Phototherapy for Hyperbilirubinemia. ( 29035896 )
2018
49
Systemic regulation of bilirubin homeostasis: Potential benefits of hyperbilirubinemia. ( 29059457 )
2018
50
Double versus single intensive phototherapy with LEDs in treatment of neonatal hyperbilirubinemia. ( 29095431 )
2018

Variations for Bilirubin Metabolic Disorder

ClinVar genetic disease variations for Bilirubin Metabolic Disorder:

6 (show all 34)
# Gene Variation Type Significance SNP ID Assembly Location
1 UGT1A1 NM_000463.2(UGT1A1): c.476T> C (p.Ile159Thr) single nucleotide variant Uncertain significance rs587784539 GRCh38 Chromosome 2, 233760763: 233760763
2 UGT1A1 NM_000463.2(UGT1A1): c.479T> A (p.Val160Glu) single nucleotide variant Uncertain significance rs587784540 GRCh37 Chromosome 2, 234669412: 234669412
3 UGT1A1 NM_000463.2(UGT1A1): c.141C> A (p.Ile47=) single nucleotide variant Uncertain significance rs34526305 GRCh37 Chromosome 2, 234669074: 234669074
4 UGT1A1 NM_000463.2(UGT1A1): c.141C> A (p.Ile47=) single nucleotide variant Uncertain significance rs34526305 GRCh38 Chromosome 2, 233760428: 233760428
5 UGT1A1 NM_000463.2(UGT1A1): c.141C> T (p.Ile47=) single nucleotide variant Conflicting interpretations of pathogenicity rs34526305 GRCh37 Chromosome 2, 234669074: 234669074
6 UGT1A1 NM_000463.2(UGT1A1): c.141C> T (p.Ile47=) single nucleotide variant Conflicting interpretations of pathogenicity rs34526305 GRCh38 Chromosome 2, 233760428: 233760428
7 UGT1A1 NM_000463.2(UGT1A1): c.322C> T (p.Arg108Cys) single nucleotide variant Uncertain significance rs587784538 GRCh37 Chromosome 2, 234669255: 234669255
8 UGT1A1 NM_000463.2(UGT1A1): c.322C> T (p.Arg108Cys) single nucleotide variant Uncertain significance rs587784538 GRCh38 Chromosome 2, 233760609: 233760609
9 UGT1A1 NM_000463.2(UGT1A1): c.476T> C (p.Ile159Thr) single nucleotide variant Uncertain significance rs587784539 GRCh37 Chromosome 2, 234669409: 234669409
10 UGT1A1 NM_000463.2(UGT1A1): c.479T> A (p.Val160Glu) single nucleotide variant Uncertain significance rs587784540 GRCh38 Chromosome 2, 233760766: 233760766
11 UGT1A1 NM_000463.2(UGT1A1): c.674T> G (p.Val225Gly) single nucleotide variant Conflicting interpretations of pathogenicity, other rs35003977 GRCh37 Chromosome 2, 234669607: 234669607
12 UGT1A1 NM_000463.2(UGT1A1): c.674T> G (p.Val225Gly) single nucleotide variant Conflicting interpretations of pathogenicity, other rs35003977 GRCh38 Chromosome 2, 233760961: 233760961
13 UGT1A1 NM_000463.2(UGT1A1): c.748T> C (p.Ser250Pro) single nucleotide variant Uncertain significance rs57307513 GRCh37 Chromosome 2, 234669681: 234669681
14 UGT1A1 NM_000463.2(UGT1A1): c.748T> C (p.Ser250Pro) single nucleotide variant Uncertain significance rs57307513 GRCh38 Chromosome 2, 233761035: 233761035
15 UGT1A1 NM_000463.2(UGT1A1): c.996+15T> C single nucleotide variant Conflicting interpretations of pathogenicity rs4148327 GRCh37 Chromosome 2, 234675826: 234675826
16 UGT1A1 NM_000463.2(UGT1A1): c.996+15T> C single nucleotide variant Conflicting interpretations of pathogenicity rs4148327 GRCh38 Chromosome 2, 233767180: 233767180
17 UGT1A1 NM_000463.2(UGT1A1): c.1084+1G> T single nucleotide variant Pathogenic rs587784535 GRCh37 Chromosome 2, 234676583: 234676583
18 UGT1A1 NM_000463.2(UGT1A1): c.1084+1G> T single nucleotide variant Pathogenic rs587784535 GRCh38 Chromosome 2, 233767937: 233767937
19 UGT1A1 NM_000463.2(UGT1A1): c.1231G> T (p.Val411Leu) single nucleotide variant Uncertain significance rs36076514 GRCh37 Chromosome 2, 234677012: 234677012
20 UGT1A1 NM_000463.2(UGT1A1): c.1231G> T (p.Val411Leu) single nucleotide variant Uncertain significance rs36076514 GRCh38 Chromosome 2, 233768366: 233768366
21 UGT1A1 NM_000463.2(UGT1A1): c.1354G> T (p.Val452Leu) single nucleotide variant Uncertain significance rs587784536 GRCh37 Chromosome 2, 234680957: 234680957
22 UGT1A1 NM_000463.2(UGT1A1): c.1354G> T (p.Val452Leu) single nucleotide variant Uncertain significance rs587784536 GRCh38 Chromosome 2, 233772311: 233772311
23 UGT1A1 NM_000463.2(UGT1A1): c.1413G> A (p.Ala471=) single nucleotide variant Uncertain significance rs587784537 GRCh37 Chromosome 2, 234681016: 234681016
24 UGT1A1 NM_000463.2(UGT1A1): c.1413G> A (p.Ala471=) single nucleotide variant Uncertain significance rs587784537 GRCh38 Chromosome 2, 233772370: 233772370
25 UGT1A1 NM_000463.2(UGT1A1): c.238_239insGTAC (p.Pro80Argfs) insertion Pathogenic rs797046090 GRCh38 Chromosome 2, 233760525: 233760526
26 UGT1A1 NM_000463.2(UGT1A1): c.238_239insGTAC (p.Pro80Argfs) insertion Pathogenic rs797046090 GRCh37 Chromosome 2, 234669171: 234669172
27 UGT1A1 NM_000463.2(UGT1A1): c.722_723del (p.Glu241Glyfs) deletion Pathogenic rs797046091 GRCh38 Chromosome 2, 233761009: 233761010
28 UGT1A1 NM_000463.2(UGT1A1): c.722_723del (p.Glu241Glyfs) deletion Pathogenic rs797046091 GRCh37 Chromosome 2, 234669655: 234669656
29 UGT1A1 NM_000463.2(UGT1A1): c.1091C> T (p.Pro364Leu) single nucleotide variant Pathogenic/Likely pathogenic rs34946978 GRCh38 Chromosome 2, 233768226: 233768226
30 UGT1A1 NM_000463.2(UGT1A1): c.1091C> T (p.Pro364Leu) single nucleotide variant Pathogenic/Likely pathogenic rs34946978 GRCh37 Chromosome 2, 234676872: 234676872
31 F12 NM_000505.3(F12): c.983C> G (p.Thr328Arg) single nucleotide variant Pathogenic rs118204456 GRCh37 Chromosome 5, 176831232: 176831232
32 F12 NM_000505.3(F12): c.983C> G (p.Thr328Arg) single nucleotide variant Pathogenic rs118204456 GRCh38 Chromosome 5, 177404231: 177404231
33 UGT1A1 NM_000463.2(UGT1A1): c.1456T> G (p.Tyr486Asp) single nucleotide variant Pathogenic rs34993780 GRCh37 Chromosome 2, 234681059: 234681059
34 UGT1A1 NM_000463.2(UGT1A1): c.1456T> G (p.Tyr486Asp) single nucleotide variant Pathogenic rs34993780 GRCh38 Chromosome 2, 233772413: 233772413

Expression for Bilirubin Metabolic Disorder

Search GEO for disease gene expression data for Bilirubin Metabolic Disorder.

Pathways for Bilirubin Metabolic Disorder

Pathways related to Bilirubin Metabolic Disorder according to KEGG:

38
# Name Kegg Source Accession
1 Porphyrin and chlorophyll metabolism hsa00860
2 ABC transporters hsa02010
3 Bile secretion hsa04976

Pathways related to Bilirubin Metabolic Disorder according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.22 ABCC2 ALB HMOX1 SLC17A5 SLC22A7 SLC35A2
2 12.22 ABCC2 G6PD UGT1A1 UGT1A6 UGT1A7 UGT1A8
3
Show member pathways
12.21 HMOX1 UGT1A1 UGT1A6 UGT1A7 UGT1A8
4
Show member pathways
11.77 ABCC2 SLCO1B1 UGT1A1
5 11.66 ABCC2 G6PD GGT1 HMOX1 UGT1A1 UGT1A6
6
Show member pathways
11.63 ABCC2 UGT1A1 UGT1A6 UGT1A8
8 11.54 ABCC2 SLC22A7 SLCO1B1
9
Show member pathways
11.49 UGT1A1 UGT1A6 UGT1A7 UGT1A8
10
Show member pathways
11.43 ABCC2 NR1I3 UGT1A1 UGT1A6
11 11.35 UGT1A1 UGT1A6 UGT1A7
12
Show member pathways
11.18 UGT1A1 UGT1A6 UGT1A8
13 10.96 ABCC2 NR1I3 UGT1A1 UGT1A6
14 10.9 UGT1A6 UGT1A8
15
Show member pathways
10.87 ABCC2 SLCO1B1
16
Show member pathways
10.85 ABCC2 SLCO1B1 UGT1A1 UGT1A6 UGT1A7 UGT1A8
17 10.81 ABCC2 NR1I3 SLCO1B1
18 10.76 G6PD GPT

GO Terms for Bilirubin Metabolic Disorder

Cellular components related to Bilirubin Metabolic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum GO:0005783 9.7 ALB HMOX1 SLC35A2 UGT1A1 UGT1A6 UGT1A7
2 extracellular space GO:0005615 9.56 ADAMTS13 ALB F12 F2 GGT1 GPT
3 intracellular membrane-bounded organelle GO:0043231 9.1 G6PD HMOX1 UGT1A1 UGT1A6 UGT1A7 UGT1A8

Biological processes related to Bilirubin Metabolic Disorder according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of catalytic activity GO:0043086 9.67 UGT1A1 UGT1A7 UGT1A8
2 hemostasis GO:0007599 9.61 ADAMTS13 F12 F2
3 fibrinolysis GO:0042730 9.58 F12 F2
4 acute-phase response GO:0006953 9.58 F2 HP UGT1A1
5 blood coagulation, intrinsic pathway GO:0007597 9.57 F12 F2
6 zymogen activation GO:0031638 9.56 F12 GGT1
7 positive regulation of blood coagulation GO:0030194 9.55 F12 F2
8 regulation of blood coagulation GO:0030193 9.54 F12 F2
9 organic anion transport GO:0015711 9.52 SLC22A7 SLCO1B1
10 thyroid hormone transport GO:0070327 9.51 ABCC2 SLCO1B1
11 cellular glucuronidation GO:0052695 9.5 UGT1A1 UGT1A6 UGT1A7
12 coumarin metabolic process GO:0009804 9.48 UGT1A7 UGT1A8
13 heme catabolic process GO:0042167 9.46 HMOX1 UGT1A1
14 retinoic acid metabolic process GO:0042573 9.43 UGT1A1 UGT1A7 UGT1A8
15 negative regulation of steroid metabolic process GO:0045939 9.37 UGT1A1 UGT1A8
16 flavone metabolic process GO:0051552 9.33 UGT1A1 UGT1A7 UGT1A8
17 xenobiotic glucuronidation GO:0052697 9.26 UGT1A1 UGT1A6 UGT1A7 UGT1A8
18 flavonoid glucuronidation GO:0052696 8.92 UGT1A1 UGT1A6 UGT1A7 UGT1A8

Molecular functions related to Bilirubin Metabolic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.88 G6PD HMOX1 UGT1A1 UGT1A6 UGT1A7 UGT1A8
2 transferase activity, transferring glycosyl groups GO:0016757 9.67 UGT1A1 UGT1A6 UGT1A7 UGT1A8
3 transferase activity, transferring hexosyl groups GO:0016758 9.56 UGT1A1 UGT1A6 UGT1A7 UGT1A8
4 enzyme inhibitor activity GO:0004857 9.5 UGT1A1 UGT1A7 UGT1A8
5 sodium-independent organic anion transmembrane transporter activity GO:0015347 9.46 SLC22A7 SLCO1B1
6 glucuronosyltransferase activity GO:0015020 9.46 UGT1A1 UGT1A6 UGT1A7 UGT1A8
7 organic anion transmembrane transporter activity GO:0008514 9.43 ABCC2 SLC22A7
8 retinoic acid binding GO:0001972 9.26 UGT1A1 UGT1A6 UGT1A7 UGT1A8
9 UDP-glycosyltransferase activity GO:0008194 8.92 UGT1A1 UGT1A6 UGT1A7 UGT1A8

Sources for Bilirubin Metabolic Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....